Genentech Inc

Type: Company

Name: Genentech Inc

Fact Sheet: Fact Sheet for Genentech, Inc

First reported 11 hours ago - Updated 11 hours ago - 1 reports

Relypsa Names John Orwin as Chief Executive Officer

(Close-Up Media via COMTEX News Network) -- Relypsa, Inc., a biopharmaceutical company advancing lead product candidate, patiromer (RLY5016) for the treatment of hyperkalemia, in a pivotal Phase 3 clinical study, announced the appointment of John Orwin ... [Published PredictWallStreet - 11 hours ago]

Entities: Relypsa Inc, Patiromer, John Orwin

First reported 15 hours ago - Updated 15 hours ago - 1 reports

University of California San Diego

EVENT: Survivor Beach to 'SUP-port' Quest to Conquer Cancer June 2

The 7th Annual Survivor Beach Event Will Feature New Stand-Up Paddleboard (SUP) CompetitionPress Release from Supconnect Media - spreading the news on behalf of: UC San Diego NewsREGISTER FOR THE EVENT HERE: Survivor Beach SUP EventLA JOLLA, California ... [Published Malakye.com - 15 hours ago]

Entities: Cancer, University of California San Diego, Moores

First reported 19 hours ago - Updated 18 hours ago - 3 reports

Roche Holding AG

Regeneron settles all pending litigation with Roche's Genentech

Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap. ... [Published XE - 18 hours ago]

Entities: Genentech Inc, Regeneron, Roche Holding AG, Litigation

First reported 22 hours ago - Updated 22 hours ago - 1 reports

MedImmune Inc

Supreme Court Grants Certiorari In Dispute Over Cardiac Device Patents

WASHINGTON, D.C. - The question of whether a patent licensee bears the burden of proving that its products do not infringe in a declaratory judgment action filed pursuant to MedImmune Inc. v. Genentech Inc. (549 U.S. 118, 137 $(2007$)) will be decided ... [Published Mealey - 22 hours ago]

Entities: Supreme Court, Declaratory Judgment, MedImmune Inc, Writ of Certiorari

First reported May 20 2013 - Updated May 20 2013 - 1 reports

bluebird bio Appoints Two New Members to Its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced that Wendy Dixon, ... [Published Pharmacy Choice - May 20 2013]

Entities: Gene Therapy, Oncology, Doctor of Philosophy, Cancer, Genentech Inc

First reported May 18 2013 - Updated May 18 2013 - 2 reports

Genentech Inc

Briefs -- Published May 18, 2013

STOCKTON - Find out about the signs of stroke from 10 a.m. to 4 p.m. Thursday at the WorkNet Building, 56 S. Lincoln St.The event, sponsored by Stockton nonprofit Healings in Motion and Genentech, is free but requires an RSVP.It will include screenings ... [Published Recordnet.com - May 18 2013]

Entities: Genentech Inc, Ultrasound, Glucose

First reported May 16 2013 - Updated May 17 2013 - 2 reports

Sanofi SA

Patent Watch: Sanofi-Aventis Deutschland GmbH v. Genentech, Inc.

U.S. courts have the power to enjoin parties from pursuing litigation before foreign tribunals. "[I]n evaluating a request for an anti-suit injunction, [the district court] must determine (1) 'whether or not the parties and the issues are the same, and ... [Published JD Supra - May 17 2013]

Entities: Genentech Inc, Injunction, Sanofi SA, Arbitration

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Hillsboro Budget: city will dip into reserves in next fiscal year after tepid property tax revenue growth

HILLSBORO -- With the parade of good economic news passing through Hillsboro in the past year, Finance Director Suzanne Linneen said city leaders should be jumping with joy.To recap: Intel is investing billions more, cloning its 1.1 million-square-foot ... [Published Oregonian - May 16 2013]

Entities: Revenue Growth, Fiscal Year, Genentech Inc

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

(GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small ... [Published Morningstar.com - May 16 2013]

Entities: Curis Incorporated, Erivedge, Vismodegib, basal cell carcinoma

First reported May 16 2013 - Updated May 16 2013 - 3 reports

Genentech, Astellas announce FDA approval of Tarceva tablets

Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). ... [Published PBR - News - May 16 2013]

Entities: erlotinib, Astellas Pharma Inc, Genentech Inc, FDA Food & Drug Administration

First reported May 15 2013 - Updated May 16 2013 - 2 reports

Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study

Luke TimmermanGenentech has been searching for years to find a way to improve upon rituximab ( Rituxan ), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally ... [Published Xconomy - May 15 2013]

Entities: Genentech Inc, rituximab, chlorambucil, Rituxan, Antibody

First reported May 14 2013 - Updated May 15 2013 - 11 reports

FDA approves Genentech drug for lung cancer with genetic mutation

Alaric DeArmentThe Food and Drug Administration has approved a drug for a type of lung cancer. ... [Published Drug Store News - May 15 2013]

Entities: Lung Cancer, Genentech Inc, FDA Food & Drug Administration

Quotes

...illustration of the community's support in the battle against cancer," said Scott Lippman, MD, director of UC San Diego Moores Cancer Center. "The generosity of our community members and corporate partners is essential to our efforts to find new ways to defeat cancer. At UC San Diego Moores Cancer Center, we are dedicated to translating promising scientific discoveries into new, better options for our patients."

EVENT: Survivor Beach to 'SUP-port' Quest to Conquer Cancer June 2 [Published Malakye.com - 15 hours ago]

...And that could spur a major shift in the development timelines being provided by many drug developers. "A couple of years ago the big story was that immunotherapy can work" said Jedd Wolchok, director of immunotherapy at the Ludwig Center at Memorial Sloan-Kettering Cancer Center...

Bristol Myers Squibb And The New Wave Of Cancer Drugs [Published Seeking Alpha - 20 hours ago]

...candidate KPT-330 in two oncology indications through full clinical development," stated Michael Kauffman, chief executive officer of Karyopharm. "We appreciate the support of our current and new investors."

Pakianathan joins Karyopharm Therapeutics board on heels of $48.2M funding [Published India New England - 22 hours ago]

In the 2007 case MedImmune Inc. v. Genentech Inc., the U S Supreme Court "provided licensees with a shield from the economic consequences of challenging their licensors' patents while enabling those licensees to file declaratory judgment suits to clarify the rights and obligations of the parties under their license agreements" according to the ruling

Supreme Court Takes Up Medtronic's Patent Fight [Published Courthouse News Service - 23 hours ago]

More Content

sort by: Date \| Relevance
PharmaPoint: Multiple Sclerosis - Germany Drug ... [Published Individual.com - 2 hours ago]
Schrödinger Named Bio-IT World Best Practices G... [Published Prlog - 3 hours ago]
US EQUITY OPENING NEWS INCLUDING: JPMorgan plan... [Published Proactiveinvestors United Kingdom RSS feed - 4 hours ago]
Frontrunning: May 21 [Published Zero Hedge - 5 hours ago]
PharmaPoint: Multiple Sclerosis - China Drug Fo... [Published TradingCharts.com - 9 hours ago]
Relypsa Names John Orwin as Chief Executive Off... [Published PredictWallStreet - 11 hours ago]
Dr. Mark T. Kresnak Joins Dickstein Shapiro’s I... [Published Dickstein Shapiro LLP - 15 hours ago]
EVENT: Survivor Beach to 'SUP-port' Quest to Co... [Published Malakye.com - 15 hours ago]
Academy of Art University Web Design and New Me... [Published Digital Journal - 18 hours ago]
Regeneron settles all pending litigation with R... [Published XE - 18 hours ago]
Regeneron settles all pending litigation with R... [Published Reuters - 18 hours ago]
Regeneron (REGN) and Genentech Strike Deal on W... [Published Street Insider - 19 hours ago]
Program for Breakthrough Biomedical Research to... [Published UC Newswire - 20 hours ago]
Bristol Myers Squibb And The New Wave Of Cancer... [Published Seeking Alpha - 20 hours ago]
Yahoo, Tumblr, and the Loyalty Factor [Published Harvard Business Review - 22 hours ago]
Pakianathan joins Karyopharm Therapeutics board... [Published India New England - 22 hours ago]
Supreme Court Grants Certiorari In Dispute Over... [Published Mealey - 22 hours ago]
Supreme Court Takes Up Medtronic's Patent Fight [Published Courthouse News Service - 23 hours ago]
Yahoo, Tumblr, and the Loyalty Factor [Published HBR Blog Network - May 20 2013]
John Doerr's plan to reclaim the venture capita... [Published Chicago Tribune - May 20 2013]
LUNGevity Foundation Hosts Second Annual Ping P... [Published TickerTech.com - May 20 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published Scottrade - May 20 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published FinanzNachrichten.de - May 20 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Pharmacy Choice - May 20 2013]
Competitor Analysis: Thrombolytics & Fibrinolytics [Published Individual.com - May 20 2013]
Movers & shakers: May 20, 2013 [Published TheDeal.com - May 20 2013]
"Aubagio (Multiple Sclerosis) - Forecast and Ma... [Published Live-PR.com - May 20 2013]
Relypsa Names John Orwin as CEO [Published PredictWallStreet - May 20 2013]
Novartis drug Afinitor extends time without dis... [Published PharmaBiz - May 20 2013]
Briefs -- Published May 18, 2013 [Published Recordnet.com - May 18 2013]

sort by: Date \| Relevance
Frontrunning: May 21 [Published Zero Hedge - 5 hours ago] IMF Tells Central Europe to Spend More ( WSJ ) Tornadoes Blast Oklahoma ( WSJ ) Frenetic search for survivors as 91 feared dead in tornado-hit Oklahoma ( Reuters ) JPMorgan investors on edge over vote on Dimon; what if they win? ( Reuters ) Wealthy ...
Yahoo, Tumblr, and the Loyalty Factor [Published HBR Blog Network - May 20 2013] As Yahoo goes through with its acquisition of Tumblr , CEO Marissa Mayer may have a user rebellion on her hands. The early reaction from the Tumblr community is not encouraging — blogs lit up with memes of crying babies and apocalyptic rants upon ...
Genentech, Astellas announce FDA approval of Ta... [Published PBR - News - May 16 2013] Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). ...
The Myriad Case and "Gene" Patents: Much Ado ab... [Published Patent Docs - May 15 2013] By Kevin E. Noonan -- The biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA (and the DNA from other species) ...
Genentech to Present Important New Data Reflect... [Published EquityJungle - v0.1 - May 15 2013] Filed under: Investing Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early Stage Data on Investigational ...

sort by: Date \| Relevance
IMS Health and Remedy Informatics Announce Real... [Published Business Wire - May 17 2013]
Genentech’s Obinutuzumab (GA101) Significantly ... [Published EON Science - May 15 2013]
Genentech’s Obinutuzumab (GA101) Significantly ... [Published Business Wire Health News - May 15 2013]
Genentech to Present Important New Data Reflect... [Published EON Science - May 15 2013]
Genentech to Present Important New Data Reflect... [Published Business Wire Science: Science News - May 15 2013]